DOCSLIB.ORG

Inaugural-Dissertation Zur Erlangung Des Doktorgrades Der

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Inaugural-Dissertation Zur Erlangung Des Doktorgrades Der Role of TNFα and hepatic glutamine synthetase in pathogenesis of hepatic encephalopathy. Inaugural-Dissertation zur Erlangung des Doktorgrades der Mathematisch-Naturwissenschaftlichen Fakultät der Heinrich-Heine-Universität Düsseldorf vorgelegt von Vitaly Pozdeev aus Pavlograd, USSR Düsseldorf, October 2018 aus dem Institut für Molekulare Medizin II der Heinrich-Heine-Universität Düsseldorf Gedruckt mit der Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät der Heinrich-Heine-Universität Düsseldorf Berichterstatter: 1.Prof. Dr. Philipp Lang 2. Prof. Dr. Eckhard Lammert Tag der mündlichen Prüfung: 11.10.2018 (bitte bei der Abgabe Ihrer Dissertation noch offen lassen) (bitte bei der Abgabe Ihrer Dissertation noch offen lassen) ii Table of content Table of figures ........................................................................................................... vi List of tables .............................................................................................................. vii Abstract .................................................................................................................... viii Zusammenfassung ...................................................................................................... x Acknowledgment ....................................................................................................... xii List of abbreviations .................................................................................................. xiii 1. Introduction ............................................................................................................. 1 1.1 Liver anatomy. .................................................................................................. 1 1.1.1 Gross anatomy. ....................................................................................................... 1 1.1.2 Cellular anatomy. ..................................................................................................... 2 1.1.2.1 Parenchymal cells. ............................................................................................... 2 1.1.2.1.1 Hepatocytes. ...................................................................................................... 2 Ammonia and glutamine metabolism. ........................................................................................ 3 Blood protein synthesis. ............................................................................................................. 5 Drugs and xenobiotics metabolism. ........................................................................................... 5 Lipid metabolism. ........................................................................................................................ 6 Liver zonation. ............................................................................................................................ 7 1.1.2. Nonparenchymal cells. ........................................................................................... 7 1.1.2.2 Sinusoidal endothelial cells. ................................................................................. 7 1.1.2.3 Kupffer cells. ......................................................................................................... 9 1.1.2.4 Stellate cells. ...................................................................................................... 10 1.1.2.5 Dendritic cells. .................................................................................................... 10 1.1.2.6 Lymphocytes. ..................................................................................................... 11 NK cells. ................................................................................................................................... 11 NKT cells. ................................................................................................................................. 12 T cells. ...................................................................................................................................... 12 Th cells. ................................................................................................................................ 13 Cytotoxic T-cells. .................................................................................................................. 13 1.2 Liver damage .................................................................................................. 14 1.2.1 Chemokines and cytokines. ................................................................................... 14 Chemokines. ............................................................................................................................. 14 Cytokines. ................................................................................................................................. 15 Tumor necrosis factor. ......................................................................................................... 15 IL-6. ...................................................................................................................................... 16 Transforming growth factor-β. .............................................................................................. 17 iii 1.2.2 Infectious disease .................................................................................................. 18 1.2.2.1 HBV .............................................................................................................................. 18 1.2.2.2 HCV .............................................................................................................................. 18 1.2.3 Non-alcoholic fatty liver disease. ........................................................................... 19 1.2.4 Liver cirrhosis. ....................................................................................................... 19 1.2.5 Hepatic encephalopathy. ....................................................................................... 20 1.2.5.1 Symptoms. .................................................................................................................... 20 1.2.5.2 Pathogenesis. ............................................................................................................... 21 Protein nitration. ................................................................................................................... 25 RNA oxidation. ..................................................................................................................... 26 Zn homeostasis. ................................................................................................................... 27 Neuroinflammation. .............................................................................................................. 28 Blood brain barrier. ............................................................................................................... 29 Na-K-Cl co-transporter. ........................................................................................................ 30 Aquaporins. .......................................................................................................................... 31 1.2.5.3 Therapy ........................................................................................................................ 32 Nutrition. ............................................................................................................................... 32 Antibiotics. ............................................................................................................................ 33 Ammonia scavengers. .......................................................................................................... 33 L-ornithine l aspartate. ......................................................................................................... 34 Polyethilene glycol. .............................................................................................................. 34 Probiotics. ............................................................................................................................. 34 N-acetylcisteine. ................................................................................................................... 34 Albumin dialysis. .................................................................................................................. 35 Minocyclin. ............................................................................................................................ 35 1.3 Death receptor-mediated apoptosis and liver. ................................................. 35 1.3.1 CD95. .................................................................................................................... 36 Role in liver disease. ................................................................................................................ 37 1.3.2 TNFα. .................................................................................................................... 38 NF-kb activation. ....................................................................................................................... 39 Apoptosis. ................................................................................................................................. 40 1.3.3 TRAIL ...................................................................................................................
Load more

Recommended publications
  • Supplementary Data
    Supplementary Data for Quantitative Changes in the Mitochondrial Proteome from Subjects with Mild Cognitive Impairment, Early Stage and Late Stage Alzheimer’s disease Table 1 - 112 unique, non-redundant proteins identified and quantified in at least two of the three analytical replicates for all three disease stages. Table 2 - MCI mitochondrial samples, Protein Summary Table 3 - MCI mitochondrial samples, Experiment 1 Table 4 - MCI mitochondrial samples, Experiment 2 Table 5 - MCI mitochondrial samples, Experiment 3 Table 6 - EAD Mitochondrial Study, Protein Summary Table 7 - EAD Mitochondrial Study, Experiment 1 Table 8 - EAD Mitochondrial Study, Experiment 2 Table 9 - EAD Mitochondrial Study, Experiment 3 Table 10 - LAD Mitochondrial Study, Protein Summary Table 11 - LAD Mitochondrial Study, Experiment 1 Table 12 - LAD Mitochondrial Study, Experiment 2 Table 13 - LAD Mitochondrial Study, Experiment 3 Supplemental Table 1. 112 unique, non-redundant proteins identified and quantified in at least two of the three analytical replicates for all three disease stages. Description Data MCI EAD LAD AATM_HUMAN (P00505) Aspartate aminotransferase, mitochondrial precursor (EC Mean 1.43 1.70 1.31 2.6.1.1) (Transaminase A) (Glutamate oxaloacetate transaminase 2) [MASS=47475] SEM 0.07 0.09 0.09 Count 3.00 3.00 3.00 ACON_HUMAN (Q99798) Aconitate hydratase, mitochondrial precursor (EC 4.2.1.3) Mean 1.24 1.61 1.19 (Citrate hydro-lyase) (Aconitase) [MASS=85425] SEM 0.05 0.17 0.18 Count 3.00 2.00 3.00 ACPM_HUMAN (O14561) Acyl carrier protein, mitochondrial
    [Show full text]
  • Analysis of the Impact of Pufas on Placental Gene Expression V2.28 Uploadx
    TECHNISCHE UNIVERSITÄT MÜNCHEN Lehrstuhl für Ernährungsmedizin Analysis of the Impact of Polyunsaturated Fatty Acids (PUFAs) on Placental Gene Expression Eva-Maria Sedlmeier Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften genehmigten Dissertation. Vorsitzender: Univ.-Prof. Dr. M. Klingenspor Prüfer der Dissertation: 1. Univ.-Prof. Dr. J. J. Hauner 2. Univ.-Prof. Dr. H. Daniel Die Dissertation wurde am 17.10.2013 bei der Technischen Universität München eingereicht und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt am 12.12.2013 angenommen. Table of contents Table of contents Table of contents ....................................................................................................... I Summary .................................................................................................................. VI Zusammenfassung ................................................................................................ VIII 1. Introduction ........................................................................................................ 1 1.1. Fetal programming - a strategy to prevent the obesity epidemic? ...........................................1 1.1.1. The obesity epidemic ........................................................................................................1 1.1.2. Fetal programming
    [Show full text]
  • Solute Carrier Transporters As Potential Targets for the Treatment of Metabolic Disease
    1521-0081/72/1/343–379$35.00 https://doi.org/10.1124/pr.118.015735 PHARMACOLOGICAL REVIEWS Pharmacol Rev 72:343–379, January 2020 Copyright © 2019 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MARTIN C. MICHEL Solute Carrier Transporters as Potential Targets for the Treatment of Metabolic Disease Tina Schumann, Jörg König, Christine Henke, Diana M. Willmes, Stefan R. Bornstein, Jens Jordan, Martin F. Fromm, and Andreas L. Birkenfeld Section of Metabolic and Vascular Medicine, Medical Clinic III, Dresden University School of Medicine (T.S., C.H., D.M.W., S.R.B.), and Paul Langerhans Institute Dresden of the Helmholtz Center Munich at University Hospital and Faculty of Medicine (T.S., C.H., D.M.W.), Technische Universität Dresden, Dresden, Germany; Deutsches Zentrum für Diabetesforschung e.V., Neuherberg, Germany (T.S., C.H., D.M.W., A.L.B.); Clinical Pharmacology and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (J.K., M.F.F.); Institute for Aerospace Medicine, German Aerospace Center and Chair for Aerospace Medicine, University of Cologne, Cologne, Germany (J.J.); Diabetes and Nutritional Sciences, King’s College London, London, United Kingdom (S.R.B., A.L.B.); Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Centre Munich at the University of Tübingen, Tübingen, Germany (A.L.B.); and Department of Internal Medicine, Division of Endocrinology, Diabetology and Nephrology, Eberhard Karls University Tübingen, Tübingen, Germany (A.L.B.) Abstract.
    [Show full text]
  • 1 SUPPLEMENTAL DATA Figure S1. Poly I:C Induces IFN-Β Expression
    SUPPLEMENTAL DATA Figure S1. Poly I:C induces IFN-β expression and signaling. Fibroblasts were incubated in media with or without Poly I:C for 24 h. RNA was isolated and processed for microarray analysis. Genes showing >2-fold up- or down-regulation compared to control fibroblasts were analyzed using Ingenuity Pathway Analysis Software (Red color, up-regulation; Green color, down-regulation). The transcripts with known gene identifiers (HUGO gene symbols) were entered into the Ingenuity Pathways Knowledge Base IPA 4.0. Each gene identifier mapped in the Ingenuity Pathways Knowledge Base was termed as a focus gene, which was overlaid into a global molecular network established from the information in the Ingenuity Pathways Knowledge Base. Each network contained a maximum of 35 focus genes. 1 Figure S2. The overlap of genes regulated by Poly I:C and by IFN. Bioinformatics analysis was conducted to generate a list of 2003 genes showing >2 fold up or down- regulation in fibroblasts treated with Poly I:C for 24 h. The overlap of this gene set with the 117 skin gene IFN Core Signature comprised of datasets of skin cells stimulated by IFN (Wong et al, 2012) was generated using Microsoft Excel. 2 Symbol Description polyIC 24h IFN 24h CXCL10 chemokine (C-X-C motif) ligand 10 129 7.14 CCL5 chemokine (C-C motif) ligand 5 118 1.12 CCL5 chemokine (C-C motif) ligand 5 115 1.01 OASL 2'-5'-oligoadenylate synthetase-like 83.3 9.52 CCL8 chemokine (C-C motif) ligand 8 78.5 3.25 IDO1 indoleamine 2,3-dioxygenase 1 76.3 3.5 IFI27 interferon, alpha-inducible
    [Show full text]
  • Clinical Features of Sodium-Taurocholate Cotransporting Polypeptide Deficiency in Pediatric Patients: Case Series and Literature Review
    1054 Case Report Clinical features of sodium-taurocholate cotransporting polypeptide deficiency in pediatric patients: case series and literature review Ting-Ting Zou, Yu Zhu, Chao-Min Wan, Qiong Liao Department of Pediatric Infectious Diseases, West China Second University Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China Correspondence to: Qiong Liao, MD. Department of Pediatric Infectious Diseases, West China Second University Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu 610041, China. Email: [email protected]. Abstract: Sodium-taurocholate cotransporting polypeptide (NTCP) deficiency is a newly reported hereditary bile acid metabolic disease. Here we describe the clinical characteristics of 12 cases of pediatric NTCP deficiency, as well as review 60 previously reported cases in the literature in order to provide better guidance for pediatricians. The clinical records, laboratory and imaging data were collected of 12 cases who were treated at the pediatric infectious disease department of the West China Second University Hospital of Sichuan University, China, from December 2018 to July 2020. PubMed and Wanfang databases were searched and 11 studies including 60 pediatric NTCP deficiency patients from January 2015 to November 2020 were retrieved. In our center, there were 4 girls and 8 boys, with a median age at admission of 9.9 months (range, 2.2 to 70 months). Six patients (50%) had prolonged neonatal jaundice. All of the patients (12/12; 100%) had normal growth and development. The reason for the first visit was prolonged neonatal jaundice (4/12, 33.3%), non-liver related diseases (6/12, 50%) and routine checkup (2/12, 16.7%).
    [Show full text]
  • Induced Toxicity in Zebrafish by Inhibition of Ornithine Aminotransferase
    RESEARCH ARTICLE Pharmacologic rescue of hyperammonemia- induced toxicity in zebrafish by inhibition of ornithine aminotransferase Matthias Zielonka1,2*, Maximilian Breuer1, JuÈrgen GuÈnther Okun1, Matthias Carl3,4, Georg Friedrich Hoffmann1, Stefan KoÈ lker1 1 University Hospital Heidelberg, Center for Child and Adolescent Medicine, Division for Pediatric Neurology and Metabolic Medicine, Heidelberg, Germany, 2 Heidelberg Research Center for Molecular Medicine (HRCMM), Heidelberg, Germany, 3 Heidelberg University, Medical Faculty Mannheim, Department of Cell a1111111111 and Molecular Biology, Mannheim, Germany, 4 University of Trento, Center for Integrative Biology (CIBIO), a1111111111 Laboratory of Translational Neurogenetics, Trento, Italy a1111111111 a1111111111 * [email protected] a1111111111 Abstract Hyperammonemia is the common biochemical hallmark of urea cycle disorders, activating OPEN ACCESS neurotoxic pathways. If untreated, affected individuals have a high risk of irreversible brain Citation: Zielonka M, Breuer M, Okun JG, Carl M, damage and mortality. Here we show that acute hyperammonemia strongly enhances trans- Hoffmann GF, KoÈlker S (2018) Pharmacologic amination-dependent formation of osmolytic glutamine and excitatory glutamate, thereby rescue of hyperammonemia-induced toxicity in zebrafish by inhibition of ornithine inducing neurotoxicity and death in ammoniotelic zebrafish larvae via synergistically acting aminotransferase. PLoS ONE 13(9): e0203707. overactivation of NMDA receptors and bioenergetic
    [Show full text]
  • Program in Human Neutrophils Fails To
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 is online at: average * The Journal of Immunology Anaplasma phagocytophilum , 20 of which you can access for free at: 2005; 174:6364-6372; ; from submission to initial decision 4 weeks from acceptance to publication J Immunol doi: 10.4049/jimmunol.174.10.6364 http://www.jimmunol.org/content/174/10/6364 Insights into Pathogen Immune Evasion Mechanisms: Fails to Induce an Apoptosis Differentiation Program in Human Neutrophils Dori L. Borjesson, Scott D. Kobayashi, Adeline R. Whitney, Jovanka M. Voyich, Cynthia M. Argue and Frank R. DeLeo cites 28 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2005/05/03/174.10.6364.DC1 This article http://www.jimmunol.org/content/174/10/6364.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* • Why • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Insights into Pathogen Immune Evasion Mechanisms: Anaplasma phagocytophilum Fails to Induce an Apoptosis Differentiation Program in Human Neutrophils1 Dori L.
    [Show full text]
  • Supplemental Figure 1: Immunoelectron Microscopy of Ribeye on the Harvested Sucrose Pellet from the Gradient Centrifugation Shown in Multiple Panels
    Supplemental Figure 1: Immunoelectron microscopy of ribeye on the harvested sucrose pellet from the gradient centrifugation shown in multiple panels. Supplemental Figure 2: Immunoelectron microscopy of VAMP2 on the harvested 200-400 mM sucrose interface sample shown in multiple panels. Supplemental Figure 3: A. Western blots indicate the immunoprecipitation of ribeye and CtBP2 with the CtBP2 antibody. Also coimmunoprecipitation of CtBP1, actin, myosin 9H, spectrin and α-tubulin is shown. B. Western blots indicate the immunoprecipitation of only ribeye with the AD antibody and the coimmunoprecipitation of PRPF39 is indicated. Supplemental Figure 4. Colocalization of ribeye with various presynaptic proteins. The labeling of individual proteins is presented in grayscale and merged panels are depicted in color. Double-labeling with ribeye-specific antiserum reveals the localization with respect to synaptic ribbons of SNARE proteins such as syntaxin 1 (A-C), SNAP25 (D-F), VAMP2 (G-I), syntaxin 6 (J-L), SNAP23 (M-O), VAMP7 (P-R), VAP-33 (S-U); SNARE dissociation molecules such as α-SNAP, β-SNAP (V-X), NSF (Y-A′); hair-cell specific proteins such as glutamate receptors 2 and 3 (GluR2 and GluR3) (B′-D′), glutamate transporter vGluT3 (E′-G′), hair-cell specific Ca2+ channel Cav1.3 (H′-J′), calcium sensor otoferlin (K′-M′); and other synaptic proteins such as rabphilin (N′-P′), munc 18 (Q′-S′), and synapsin (T′-V′). Supplemental Figure 5. Colocalization of ribeye with endocytotic and vesicle- trafficking proteins. The labeling of individual proteins is presented in grayscale and merged panels are depicted in color. Double-labeling with ribeye-specific antiserum reveals the localization of the endocytic proteins clathrin (A-C), dynamin (D-F), SCAMP1 (G-I) and endophilin (J-L) and of the trafficking proteins Sec13 (M-O), β-COP (P-R), VCP (S-U), and GAPDH (V-X) with respect to synaptic ribbons.
    [Show full text]
  • Five Day IL-15Cx Treatment Results in Splenic CD8+ T Cell Activation and Up-Regulation of Cytotoxic Molecule Expression in Pymt Tumor-Bearing Mice
    A Vehicle IL-15cx treated Events CD71 CD98 CD44 GZMB B 60 P = 0.03 300 P = 0.005 100 4000 P = 0.02 P < 0.0001 ) ) ) 80 3000 FI FI FI 40 200 (%) 60 high (gM (gM 2000 44 98 71 40 (gM MB 20 100 CD CD CD GZ 1000 20 0 0 0 0 Vehicle IL-15cx Vehicle IL-15cx Vehicle IL-15cx Vehicle IL-15cx Supplemental Figure 1: Five day IL-15cx treatment results in splenic CD8+ T cell activation and up-regulation of cytotoxic molecule expression in PyMT tumor-bearing mice. (A,B) Vehicle or IL-15cx was injected for five days (days 0 - 4) into PyMT tumor-bearing mice, as depicted in Fig.1C, and splenocytes were assayed on day 5. (A) Phenotype of splenic CD8+ T cells in vehicle versus IL-15cx treated PyMT tumor bearing mice. CD71 (transferrin receptor) and CD98 (large neutral amino acid trans- porter, or LAT1) are up-regulated on T cells upon activation and growth (ref. 28 and not shown). As indicated, filled histograms are CD8+ splenocytes from mice treated with vehicle, while line trace is with IL-15cx. (B) As in A, but for multiple samples. These data are representative of two independent experiments. Error bars indicate S.D., and P-values are from student’s unpaired t-test. A Unsorted tumor Splenic CD8+CD44high + IL-15 CD8+CD44high + IL-15 Events CD71 B C Splenic only Tumor:Splenic 512 71% 1:10 High IL-2 stimulation/ 59% no tumor suspension 256 128 1:1 36% 64 CD71 gMFI 32 10:1 22% 16 Low IL-2 stimulation/ 0 no tumor suspension 1:10 1:1 10:1 Events Ratio tumor suspension: Splenocyte CD71 splenocyte suspension Supplemental Figure 2: PyMT tumor single-cell suspensions induce IL-2 / IL-15 resistance in CD8+ T cells.
    [Show full text]
  • Solute Carrier Transporters As Potential Targets for the Treatment of Metabolic Disease
    1521-0081/72/1/343–379$35.00 https://doi.org/10.1124/pr.118.015735 PHARMACOLOGICAL REVIEWS Pharmacol Rev 72:343–379, January 2020 Copyright © 2019 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MARTIN C. MICHEL Solute Carrier Transporters as Potential Targets for the Treatment of Metabolic Disease Tina Schumann, Jörg König, Christine Henke, Diana M. Willmes, Stefan R. Bornstein, Jens Jordan, Martin F. Fromm, and Andreas L. Birkenfeld Section of Metabolic and Vascular Medicine, Medical Clinic III, Dresden University School of Medicine (T.S., C.H., D.M.W., S.R.B.), and Paul Langerhans Institute Dresden of the Helmholtz Center Munich at University Hospital and Faculty of Medicine (T.S., C.H., D.M.W.), Technische Universität Dresden, Dresden, Germany; Deutsches Zentrum für Diabetesforschung e.V., Neuherberg, Germany (T.S., C.H., D.M.W., A.L.B.); Clinical Pharmacology and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (J.K., M.F.F.); Institute for Aerospace Medicine, German Aerospace Center and Chair for Aerospace Medicine, University of Cologne, Cologne, Germany (J.J.); Diabetes and Nutritional Sciences, King’s College London, London, United Kingdom (S.R.B., A.L.B.); Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Centre Munich at the University of Tübingen, Tübingen, Germany (A.L.B.); and Department of Internal Medicine, Division of Endocrinology, Diabetology and Nephrology, Eberhard Karls University Tübingen, Tübingen, Germany (A.L.B.) Abstract.
    [Show full text]
  • The Mechanism of Transport by Mitochondrial Carriers Based on Analysis of Symmetry
    Supplementary Information Results and Discussion The mechanism of transport by mitochondrial carriers based on analysis of symmetry Alan J. Robinson, Catherine Overy and Edmund R.S. Kunji The Medical Research Council, Dunn Human Nutrition Unit, Hills Road, Cambridge, CB2 0XY, United Kingdom. Contents Supplementary text 1. Assembly of symmetry‐related triplets. 4 2. Conserved triplets of symmetric residues 4 3. Mitochondrial dicarboxylate carriers 6 4. Mitochondrial oxoglutarate transporters 7 5. Mitochondrial carnitine/acylcarnitine carriers 8 6. Mitochondrial ADP/ATP carriers 9 7. Mitochondrial GTP/GDP carrier 10 8. Mitochondrial phosphate transporters 12 9. Mitochondrial oxaloacetate carriers 13 10. Mitochondrial aspartate/glutamate carriers 14 11. Mitochondrial oxodicarboxylate carriers 16 12. Mitochondrial Mg2+‐ATP/Pi transporters 17 13. Mitochondrial ornithine transporters 18 14. Mitochondrial succinate/fumarate carriers 19 15. Mitochondrial citrate transporters 20 16. Mitochondrial ScMrs3p‐like transporters 21 17. Mitochondrial ScYFR045w‐like transporters 22 18. Peroxisomal adenine nucleotide transporters 23 19. Mitochondrial UCP4 orthologs 24 20. Mitochondrial UCP5 orthologs 25 1 21. Mitochondrial CoA transporters 26 22. Mitochondrial pyrimidine nucleotides transporters 27 23. Mitochondrial NAD+ transporters 28 25. Mitochondrial S‐adenosyl‐methionine transporters 30 26. Mitochondrial thiamine pyrophosphate transporters 32 27. Mitochondrial glutamate transporters 33 28. Mitochondrial MCART1 and MCART2 transporters 34 29. Mitochondrial MCART6 transporters 35 30. Mitochondrial ScYhm2p‐like transporters 36 31. Mitochondrial ScYmc1p and ScYmc2p transporters 37 32. Mitochondrial YMR166c transporters 38 33. Mitochondrial YPR011c transporters 39 34. Mitochondrial ScMtm1p and HsSLC25A39/HsSLC25A40 transporters 39 35. Mitochondrial ScYDL119c and SLC25A38 transporters 40 36. Mitochondrial HsSLC25A29 transporters 42 37. Mitochondrial HsSLC25A42 transporters 42 38. Mitochondrial HsSLC25A43 transporters 43 39.
    [Show full text]
  • Next Generation Sequencing (V10)
    Sheffield Children’s NHS Foundation Trust Department: Sheffield Diagnostic Genetics Service Title: NGS website document Document reference number: 413.004 NHS Next Generation Sequencing Service at SDGS Table of Contents Table of Contents............................................................................................................................ 1 Testing Workflow ............................................................................................................................ 3 Library Preparation...................................................................................................................... 3 Data Analysis .............................................................................................................................. 3 Post analysis ............................................................................................................................... 5 Confirmation of variants detected by NGS .................................................................................. 5 Inborn Errors of Metabolism ............................................................................................................ 6 Rhabdomyolysis / Metabolic Myopathies ................................................................................................................... 6 Familial Hypercholesterolemia panel............................................................................................... 7 Musculoskeletal Service .................................................................................................................
    [Show full text]